Akums Drugs: Down 30%
- Akums Drugs: Down 30%
- CDMO is the biggest theme; select companies can grow 5 times in next 10 years: Madhusudan Kela
- The Delhi-based contract development and manufacturing organisation (CDMO)
- Sandeep Jain, Managing Director of Akums Drugs said he expects the company's revenue to remain flattish for FY25.
- However, he will be able to maintain the margin in the CDMO business at around 15%.
- About 78% of Akums' total revenue comes from the CDMO business.
- Exports contribute around 5% of the company’s total revenue, and Jain said the aim is to maintain this level.
- The company is also putting substantial effort into its marketing business to drive growth across other segments.
- Akums is a pharmaceutical CDMO offering a comprehensive range of pharmaceutical products and services in India and overseas.
- The company has the largest capacity in the country. Its capacity utilisation stood at 40%, and can scale up to 60%.
Comments
Post a Comment